Mebendazole

Summary

Mebendazole (CHEMBL685) is an approved small-molecule antinematodal drug (ATC P02CA51); indicated across 7 conditions including helminthiasis and anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02CA51 (+1 more)
• Indications: 7 conditions
• Clinical trials: 25
• Chemistry: 295.29 Da · C16H13N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL685
Name	Mebendazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4030
ChEBI	CHEBI:6704
ATC	P02CA51, P02CA01
Molecular formula	C16H13N3O3
Molecular weight	295.29
InChIKey	OPXLLQIJSORQAM-UHFFFAOYSA-N

SMILES: COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3

IUPAC name: methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate

ChEBI definition: A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.

Pharmacological roles (ChEBI): antinematodal drug, tubulin modulator, microtubule-destabilising agent.

Also known as: Emverm, Mebendazol, Mebendazole, Mebendazole polymorph c, Mebendazolum, Mebenvet, NSC-184849, Ovitelmin, Pantelmin, R 17,635, R-17635, Telmintic

Patent coverage: 4,337 distinct patent families (14,479 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 14,001 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Inositol monophosphatase 1, ATP-binding cassette sub-family C member 4, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 2, Cytochrome P450 1A2, Cytochrome P450 2C9, Aldehyde dehydrogenase 1A1, Hypoxia-inducible factor 1-alpha, Lethal factor, Huntingtin.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 19 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4117701
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4519752
LMNA	6.05	Potency	891.3	nM	CHEMBL_ACT_3639251
CYP2C9	5.8	Potency	1585	nM	CHEMBL_ACT_5077350
P15917	5.6	Potency	2512	nM	CHEMBL_ACT_4634203
HIF1A	5.5	Potency	3162	nM	CHEMBL_ACT_4126950
HIF1A	5.5	Potency	3162	nM	CHEMBL_ACT_4520361
KDR	5.44	IC50	3600	nM	CHEMBL_ACT_12085697
CYP1A2	5.4	AC50	3981	nM	CHEMBL_ACT_6003258
KDR	5.37	IC50	4300	nM	CHEMBL_ACT_24662370
ABL1	5.34	Ki	4600	nM	CHEMBL_ACT_10884752
ABL1	5.3	IC50	5000	nM	CHEMBL_ACT_10956817
HTT	5.25	Potency	5623	nM	CHEMBL_ACT_3757443
KDR	5.06	IC50	8800	nM	CHEMBL_ACT_12085693

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
helminthiasis	4	MONDO:0004664	EFO:1001342

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anemia	3	MONDO:0002280	EFO:0004272
necatoriasis	3	MONDO:0005870	EFO:0007390
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
hookworm infectious disease	2	MONDO:0005799	EFO:0007314
glioma	1	MONDO:0021042	MONDO:0100342

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE3	8
PHASE4	6
Not specified	5
PHASE2	3
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01314937	PHASE4	COMPLETED	The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas
NCT01327469	PHASE4	COMPLETED	The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia
NCT01379326	PHASE4	COMPLETED	Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2
NCT02385058	PHASE4	COMPLETED	Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
NCT03261596	PHASE4	WITHDRAWN	Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
NCT03278431	PHASE4	COMPLETED	Triple Combinations Against Hookworm Infections in Lao
NCT03925662	PHASE3	RECRUITING	Mebendazole as Adjuvant Treatment for Colon Cancer
NCT06736691	PHASE3	ENROLLING_BY_INVITATION	Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT06800248	PHASE3	NOT_YET_RECRUITING	Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
NCT00116493	PHASE3	COMPLETED	Severe Anemia Treatment Trials, Pakistan
NCT00148629	PHASE3	COMPLETED	Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women
NCT01173562	PHASE3	COMPLETED	A Safety Study of Mebendazole in Children 2 to 10 Years of Age
NCT01350271	PHASE3	COMPLETED	Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections
NCT02034162	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
NCT01837862	PHASE1/PHASE2	COMPLETED	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
NCT03757403	PHASE2	WITHDRAWN	RDD1609 as a Treatment for Idiopathic Pruritus Ani
NCT03995680	PHASE2	COMPLETED	Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
NCT06720259	PHASE2	COMPLETED	Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura
NCT01729260	PHASE1	COMPLETED	Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
NCT02644291	PHASE1	COMPLETED	Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
NCT06335160	Not specified	RECRUITING	Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
NCT01050374	Not specified	COMPLETED	Safety and Efficacy of Drug Combinations Against Schistosomiasis
NCT01050452	Not specified	COMPLETED	Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
NCT04443049	Not specified	UNKNOWN	To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
NCT05073562	Not specified	WITHDRAWN	Nutrition Intervention to Address Anemia Among Adolescent Girls in Liberia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).